Replies to post #92044 on Biotech Values

[wbart21]

ABT+FACT...TRBN








Prior to acquisition FACT entered into a partnership with TRBN for TRU-16.Nonrefundable milestone and equity investment made at the time presumably as an attempt to thwart BIIB acquisition in the teens.Deal has a $10mm 18 month termination fee if FACT or acquiree terminates w/i timeframe.ABT today included a slide reference to the trbn program at Cowen pg 9.
**tp://tinyurl.com/yfgfno5

TRBN's other significant programs were partnered with WYE at time of its acquisition by PFE.PFE has since reaffirmed/assumed those collaborative agreements.

Trbn has about $3/sh cash,manageable burn because of the foregoing and has some early validation from some solid Co's wye,fact,pfe...perhaps ABT.Anyone familiar with the promise or lack thereof of their SMIP platform from a scientific perspective?

[DewDiligence]

ASCO will have something on the potentially registrational phase-2 trial of ABT-888 in Stage III/IV melanoma, according to today’s ABT CC. This is the trial in question:

http://clinicaltrials.gov/ct2/show/NCT00804908

ABT-888 is a dual PARP inhibitor that ABT acquired in the Facet Biotech deal.

[DewDiligence]

ABT received a $30M milestone payment from BIIB for enrollment of the first patient in the phase-3 daclizumab trial in RRMS:

http://finance.yahoo.com/news/Biogen-Idec-and-Abbott-bw-4069182014.html?x=0&.v=1